

BIOMARIN PHARMACEUTICAL INC
 Form 4
 October 31, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BAFFI ROBERT

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2014

____ Director
 Officer (give title below) _____ Other (specify below)
EVP, Technical Operations

(Street)
NOVATO, CA 94949

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ____ Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|------------------------------------|---|
| | | | Code | V | Amount | (A) or (D) | Price | | |
| Common Stock | | | | | 23,889 | I | | Shares Owned by Baffi Family Trust | |
| Common Stock | 10/29/2014 | 10/29/2014 | M | | 4,655 | A | \$ 17.54 | 103,855 | D |
| Common Stock | 10/29/2014 | 10/29/2014 | M | | 5,770 | A | \$ 17.33 | 109,625 | D |

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

| | | | | | | | | |
|--------------|------------|------------|-----|--------|---|----------------------|---------|---|
| Common Stock | 10/29/2014 | 10/29/2014 | M | 35,037 | A | \$ 38.59 | 144,662 | D |
| Common Stock | 10/29/2014 | 10/29/2014 | S V | 45,462 | D | \$ 81.0997 (1) | 99,200 | D |
| Common Stock | 10/30/2014 | 10/30/2014 | M | 27,372 | A | \$ 38.59 | 126,572 | D |
| Common Stock | 10/30/2014 | 10/30/2014 | M | 2,591 | A | \$ 38.59 | 129,163 | D |
| Common Stock | 10/30/2014 | 10/30/2014 | S V | 29,963 | D | \$ 81.6994 (2) | 99,200 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | Amount or Number of Shares | |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|----------------------------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) Common Stock | \$ 17.54 | 10/29/2014 | 10/29/2014 | A | 4,655 | 05/20/2007 ⁽³⁾ | 11/20/2016 | Common Stock | 4,655 |
| Stock Option (right to buy) Common Stock | \$ 17.33 | 10/29/2014 | 10/29/2014 | A | 5,770 | 12/07/2007 ⁽⁴⁾ | 06/07/2017 | Common Stock | 5,770 |
| Stock Option | \$ 38.59 | 10/29/2014 | 10/29/2014 | A | 35,037 | 11/22/2008 ⁽⁵⁾ | 05/21/2018 | Common Stock | 35,037 |

(right to
buy)
Common
Stock

Stock

Option

(right to
buy)

\$ 38.59 10/30/2014 10/30/2014 A 27,372 11/22/2008 05/21/2018⁽⁵⁾

Common
Stock 27,

Common
Stock

Stock

Option

(right to
buy)

\$ 38.59 10/30/2014 10/30/2014 A 2,591 11/22/2008⁽⁶⁾ 05/21/2018

Common
Stock 2,

Common
Stock

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

BAFFI ROBERT
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949

EVP, Technical Operations

Signatures

/s/ Laura Randall Woodhead,
Attorney-in-Fact

10/31/2014

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price in column 4 is a weighted average price. The price actually received ranged from \$81.00 to \$81.53. The reporting person will
(1) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price in column 4 is a weighted average price. The price actually received ranged from \$81.00 to \$81.96. The reporting person will
(2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(3) Option grant vests 6/48ths on May 20, 2007 and 1/48th on the 20th day of every month thereafter.

(4) Option grant vests 6/48ths on December 7, 2007 and 1/48th on the 7th day of every month thereafter.

(5) Option grant vests 6/48ths on November 22, 2008 and 1/48th on the 22nd day of every month thereafter.

(6) Option grant vests 6/48ths on November 22, 2008 and 1/48th on the 22nd day of every month thereafter.

(7) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.